We are live on
!
Find out more
DBG
De Burlo Group Portfolio holdings
AUM
$441M
1-Year Est. Return
21.21%
This Fund
S&P 500
This Quarter
Est. Return
-7.59%
1 Year Est. Return
+21.21%
3 Year Est. Return
+98.05%
5 Year Est. Return
+220.33%
10 Year Est. Return
+1,846.98%
AUM
$351M
AUM Growth
-$186M
(-35%)
Cap. Flow
-$133M
Cap. Flow
% of AUM
-37.85%
Top 10 Holdings %
Top 10 Hldgs %
76.44%
Holding
207
New
37
Increased
22
Reduced
25
Closed
123
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$35.7M |
| 2 |
McKesson
MCK
|
+$33M |
| 3 |
Elevance Health
ELV
|
+$28.2M |
| 4 |
EOG Resources
EOG
|
+$26.4M |
| 5 |
NVO
Novo Nordisk
NVO
|
+$26.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$27.1M |
| 2 |
Berkshire Hathaway Class B
BRK.B
|
+$24.3M |
| 3 |
UnitedHealth
UNH
|
+$22.6M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$21M |
| 5 |
Mastercard
MA
|
+$20.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 28.18% |
| 2 | Consumer Staples | 20.19% |
| 3 | Technology | 15.79% |
| 4 | Energy | 12.08% |
| 5 | Financials | 8.65% |
Similar funds
ECA
DWML
BOA
PLU
CPW
AWM
CAAM
SCP
De Burlo Group's Q2 2022 Portfolio in Review
As of Q2 2022, De Burlo Group held 207 positions worth $351M, down 35% from $537M the previous quarter. Its ten largest holdings account for 76% of the portfolio.
De Burlo Group withdrew a net $133M in Q2 2022, closing 123 positions and reducing 25 holdings. Its most notable exit was Regeneron Pharmaceuticals, an estimated $18.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 19% a quarter earlier, followed by Consumer Staples and Technology.
Against the trend, De Burlo Group opened a new position in McKesson worth $33.7M.
- De Burlo Group's largest Q2 2022 buy was McKesson: 103,170 shares worth $33.7M.
- De Burlo Group added most to Procter & Gamble in Q2 2022, an estimated $35.7M increase.
- De Burlo Group's biggest Q2 2022 reduction was Microsoft, cutting an estimated $27.1M.
- De Burlo Group fully exited Regeneron Pharmaceuticals in Q2 2022, selling an estimated $18.3M.
- De Burlo Group's ten largest holdings make up 76% of its $351M portfolio in Q2 2022.
- De Burlo Group opened 37 new positions and closed 123 in Q2 2022.
- De Burlo Group's portfolio value fell 35% quarter-over-quarter to $351M.
Based on De Burlo Group's 13F filing for Q2 2022, filed 11 Aug 2022.